eXoZymes Inc. $(EXOZ)$, a leader in AI-engineered enzymes, has reported a net loss of $2.36 million for the second quarter of 2025, contributing to a year-to-date loss of $4.22 million. This increase in net loss compared to the previous year is attributed to a $1.20 million rise in operating expenses, primarily due to expanded research and development and leadership hires aimed at driving long-term growth. The company ended the quarter with $6.99 million in cash and cash equivalents, which is expected to support operations through the first quarter of 2026. eXoZymes highlighted its selection as a core industry partner in a $9 million NSF-funded initiative, with a $3 million share to advance modular cell-free biomanufacturing and develop a production module for santalene, a high-value fragrance compound. Additionally, the company achieved a biomanufacturing breakthrough by advancing from concept to gram-scale NCT production in five months, with a 96% yield and over 99% purity.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1060160) on August 12, 2025, and is solely responsible for the information contained therein.
